智通财经APP讯，山东新华制药股份(00719)发布公告，于2026年1月14日，该公司因2021年A股股票期 权激励计划首次授予合共690.69万股A股股份。 ...

山东新华制药（000756）股份(00719)发布公告，于2026年1月14日，该公司因2021年A股股票期权激励 计划首次授予合共690.69万股A股股份。 ...

Group 1 - The State Council Information Office will hold a press conference on January 14 to discuss the import and export situation for the entire year of 2025, with the Deputy Director of the General Administration of Customs, Wang Jun, presenting the information [1] - The Taiwan Affairs Office will also hold a press conference on January 14 to address recent cross-strait hot issues [2] Group 2 - On January 14, a total of 5 companies will have their restricted shares unlocked, with a total of 7.2278 million shares released, amounting to a market value of 151 million yuan at the latest closing price [3] - The companies with the highest number of unlocked shares are Xinhua Pharmaceutical, Huace Navigation, and Ruilian New Materials, with unlocked shares of 6.3748 million, 454,500, and 269,100 respectively [3] - The companies with the highest market value of unlocked shares are Xinhua Pharmaceutical (108 million yuan), Huace Navigation (1.84892 million yuan), and Ruilian New Materials (1.26923 million yuan) [3] Group 3 - On January 14, 14 companies disclosed their stock repurchase progress, with 4 companies announcing new repurchase plans, 2 companies reporting on the implementation of repurchase plans, and 8 companies completing their repurchase plans [4] - The highest repurchase plan amounts announced are from Kaifa Electric (up to 60 million yuan), Huazhi Jie (up to 50 million yuan), and Haojiang Intelligent (up to 3 million yuan) [4] - The companies with the highest repurchase amounts implemented are Huayuan Holdings (56.5399 million yuan) and Jichuan Pharmaceutical (2.6199 million yuan) [4] Group 4 - On January 14, 11 companies announced their progress on private placements, with 4 companies disclosing new private placement plans, 2 plans approved by shareholders, 4 plans approved by the CSRC, and 1 plan halted [5] - The companies with the highest proposed fundraising amounts are Shandong Yaobang (up to 3.235 billion yuan), Fulim Precision (up to 3.175 billion yuan), and Yuanwanggu (up to 691 million yuan) [5] Group 5 - Six A-shares will have their equity registration on January 14, with all six companies planning to distribute dividends [6] - The companies with the highest dividend payouts are Yunlu Co. (5.00 yuan per 10 shares), Fuan Energy (2.50 yuan per 10 shares), and Guangdong Mingzhu (2.00 yuan per 10 shares) [6]

Market Overview - US core CPI inflation slowdown failed to maintain stock market gains, with major indices turning negative; S&P 500 down 0.19%, Dow Jones down 0.80%, and Nasdaq down 0.10% [1] - Financial sector dragged down by bank stocks, with JPMorgan falling over 4% and Visa also down more than 4% after CFO hinted at potential impacts from credit card interest rate caps [1] - Google saw a rise of over 1%, marking four consecutive days of record highs, while AMD and Intel gained over 6% and 7% respectively after rating upgrades [1] Sector Performance - Nasdaq Golden Dragon China Index fell by 1.86%, with notable declines in Brain Rejuvenation Technology down over 26% and Pinduoduo down over 5% [2] - Offshore RMB initially rose post-US CPI release but later fell below 6.97, moving away from a 20-month high [4] Commodity Market - Oil prices rose for four consecutive days, reaching a two-month high, with a peak increase of over 3% following Trump's cancellation of talks with Iran [5] - Gold hit a record high before turning down, while silver rose nearly 5% in two days, achieving historical highs [5] Company Announcements - OpenAI's first hardware, reportedly AI headphones, aims for sales of 50 million units this year [6] - META plans to double the production capacity of AI glasses Ray-Ban to 20 million units by 2026, reflecting the rapid growth of the AI glasses market [7] - TCL Technology expects a net profit of 4.21 billion to 4.55 billion yuan for 2025, a year-on-year increase of 169% to 191% [19] - Dazhu CNC anticipates a net profit of 785 million to 885 million yuan for 2025, up 160.64% to 193.84% year-on-year [20] Industry Developments - The Ministry of Industry and Information Technology (MIIT) issued a plan to enhance the development of industrial internet platforms, aiming for over 120 million connected industrial devices by 2028 [8] - The MIIT held a meeting to implement a new round of growth stabilization plans for ten key industries, emphasizing the need to resist "involution" [9] - The Ministry of Commerce announced continued anti-dumping duties on solar-grade polysilicon from the US and South Korea for five years [10]

Core Viewpoint - On January 14, a total of 5 companies had their restricted shares unlocked, with a total unlock volume of 7.2278 million shares, amounting to a market value of 151 million yuan based on the latest closing price [1] Summary by Category Unlock Volume - The companies with the highest unlock volumes are Xinhua Pharmaceutical, Huace Navigation, and Ruile New Materials, with unlock shares of 6.3748 million, 454,500, and 269,100 respectively [1] Unlock Market Value - In terms of unlock market value, Xinhua Pharmaceutical, Huace Navigation, and Ruile New Materials lead with values of 10.8 million yuan, 1.84892 million yuan, and 1.26923 million yuan respectively [1] Unlock Ratio - Regarding the proportion of unlock shares to total share capital, Xinhua Pharmaceutical, Ruile New Materials, and Huace Navigation have the highest ratios, at 0.92%, 0.15%, and 0.06% respectively [1]

Core Viewpoint - On January 14, a total of 5 companies had their restricted shares unlocked, with a combined unlock volume of 7.2278 million shares, amounting to a market value of 151 million yuan based on the latest closing price [1] Summary by Category Unlock Volume - The companies with the highest unlock volumes were Xinhua Pharmaceutical, Huace Navigation, and Ruile New Materials, with unlock shares of 6.3748 million, 454,500, and 269,100 respectively [1] Unlock Market Value - In terms of unlock market value, Xinhua Pharmaceutical, Huace Navigation, and Ruile New Materials led with values of 10.8 million yuan, 1.84892 million yuan, and 1.26923 million yuan respectively [1] Unlock Ratio - Regarding the proportion of unlock shares to total share capital, Xinhua Pharmaceutical, Ruile New Materials, and Huace Navigation had the highest ratios at 0.92%, 0.15%, and 0.06% respectively [1]

证券代码：000756 证券简称：新华制药 公告编号：2026-01 山东新华制药股份有限公司 关于公司 2021 年 A 股股票期权激励计划首次授予 第三个行权期集中行权结果暨股份上市的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 1、本次行权的期权简称：新华 JLC2 2、本次行权的期权代码：037203 3、本次行权涉及人员 183 人，行权数量为 690.69 万份，占公司目前总股本的 1.00%。 4、本次行权采用集中行权模式。 5、本次行权股票上市流通时间为：2026 年 1 月 14 日。 2、2021 年 10 月 28 日，公司召开第十届监事会 2021 年第三次临时会议，审议通过了 《山东新华制药股份有限公司 2021 年 A 股股票期权激励计划（草案）》及其摘要的议案、 《山东新华制药股份有限公司 2021 年 A 股股票期权激励计划实施考核管理办法》的议案、 《关于核实<山东新华制药股份有限公司2021年A股股票期权激励计划首次授予激励对象名 单>》的议案。 3、2021 年 11 月 25 日，公司收到华鲁控股集团 ...

Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. is accelerating its transformation towards innovation-driven development by leveraging its strong technological foundation and research capabilities, contributing to the treatment of major diseases, particularly neurodegenerative diseases like Alzheimer's [1][3]. Group 1: Company Overview - Xinhua Pharmaceutical, as the first chemical synthesis pharmaceutical enterprise in New China, has become a significant global production and export base for antipyretic and analgesic drugs, with a deep focus on cardiovascular, anti-infection, and nervous system treatment areas [3]. - The company has established 26 products that hold the number one market share or are exclusive, with its products sold globally [3]. Group 2: Research and Development Initiatives - Xinhua Pharmaceutical has led the formation of the "Shandong Provincial Neurodegenerative Drug Research and Innovation Consortium" in collaboration with eight top institutions, targeting global medical challenges such as Alzheimer's disease [3]. - The consortium aims to create a comprehensive platform from disease mechanism research to clinical translation, focusing on the development of the first multi-target small molecule drug aimed at Aβ clearance for Alzheimer's disease [3]. - The drug OAB-14, currently in the clinical trial phase, has completed Phase I trials with good safety results, and Phase II trials are underway, marking a significant step in original drug development [3]. Group 3: Innovation and Talent Development - The company has built a closed-loop ecosystem driven by "talent-led innovation, innovation-driven industry, and industry feedback to education," supported by a high-end talent team led by 10 academicians and over 500 master's and doctoral graduates [4]. - Xinhua Pharmaceutical has established a national industry-education integration community with 110 institutions, training over 10,000 various talents in the past three years [4]. Group 4: Financial and Operational Achievements - Since the 14th Five-Year Plan, Xinhua Pharmaceutical has invested a total of 2 billion yuan in R&D, achieving 129 drug approvals, which is 5.4 times that of the 13th Five-Year Plan period [4]. - The company has set 71 national pharmaceutical industry standards and obtained 236 authorized patents, with the initial formation of three world-class bases for pharmaceutical intermediates, raw materials, and formulations [4]. - Xinhua Pharmaceutical has seen nearly 400 million USD in annual export revenue, with over 30 products passing international high-end certifications, enhancing the "International Xinhua" brand [4].

证券代码：000756 证券简称： 新华制药 公告编号：2025-75 山东新华制药股份有限公司 关于 2021 年 A 股股票期权激励计划首次授予第三个行权期行权条件成就的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述 或重大遗漏。 特别提示： 1、公司 2021 年 A 股股票期权激励计划（以下简称"本次激励计划"）首次授予第三个行权期 符合行权条件的激励对象人数为 183 人，可行权的股票期权数量为 690.69 万份，占公司目前总股本 的 1.00%，行权价格为 7.085 元/份；第三个行权期可行权股票期权若全部行权，公司股份仍具备上 市条件；本次股票期权行权采用集中行权模式。 2、本次行权事宜需在有关机构的手续办理结束后方可行权，届时将另行公告，敬请投资者注意。 山东新华制药股份有限公司（以下简称"公司"、"新华制药"）于 2025 年 12 月 31 日召开第 十一届董事会 2025 年第二次临时会议，审议通过了《关于公司 2021 年 A 股股票期权激励计划首次 授予第三个行权期行权条件成就的议案》，现将相关事项说明如下： 一、 本次激励计划已履行的相 ...

山东新华制药股份有限公司 2021 年 A 股股票期权激励计划首次授予 第三个行权期可行权激励对象名单 注：上表中部分合计数与各明细数相加之和在尾数上如有差异，系以上百分比结果四舍 五入所致。实际行权数量以中国证券登记结算有限责任公司深圳分公司登记为准。 1 序号 激励对象 职务 获授的权益 数量(万份) 首次授予第 三个行权期 可行权数量 (万份) 剩余未行 权期权总 量(万份) 本次可行权 数量占授予 的股票期权 总量比例 （%） 本次可行权 数量占目前 股本总额的 比例（%） 1 贺同庆 董事长 32 10.56 0 0.50 0.02 2 徐文辉 董事/总经理 32 10.56 0 0.50 0.02 3 徐列 董事 32 10.56 0 0.50 0.02 4 侯宁 董事/财务负责人 32 10.56 0 0.50 0.02 5 魏长生 副总经理 32 10.56 0 0.50 0.02 6 刘雪松 副总经理 20 6.6 0 0.32 0.01 7 寇祖星 副总经理 15 4.95 0 0.24 0.01 8 曹长求 董事会秘书 20 6.6 0 0.32 0.01 小计 215 70.95 0 ...